La filial de China Medical System firmó un acuerdo de novación. China Medical System's subsidiary signed a Novation Agreement.

China Medical System (00867) anunció el 3 de febrero de 2024 que su subsidiaria de propiedad absoluta celebró un acuerdo de novación con Vifor Fresenius Medical Care Renal Pharma Ltd. y Winhealth Investment para las tabletas masticables de oxihidróxido sucroférrico Velphoro®. China Medical System (00867) announced on February 3, 2024, that its wholly-owned subsidiary entered into a Novation Agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Investment for the sucroferric oxyhydroxide chewable tablets Velphoro®. El acuerdo de licencia entre Winhealth Investment y VFMCRP se firmó el 28 de junio de 2023, otorgando a Winhealth Investment una licencia exclusiva para registrar, importar, promover, distribuir, usar y vender el producto en China continental, Hong Kong, Macao y Taiwán. The License Agreement between Winhealth Investment and VFMCRP was signed on June 28, 2023, granting Winhealth Investment an exclusive license to register, import, promote, distribute, use, and sell the product in Mainland China, Hong Kong, Macao, and Taiwan.